[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Piccinin MR, Almeida JA Jr, Aydos RD, Nogueira DC, Silva RF: [Choroid metastasis of testicular primary site: case report]. Arq Bras Oftalmol; 2006 Nov-Dec;69(6):949-53
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroid metastasis of testicular primary site: case report].
  • [Transliterated title] Metástases de coróide de origem testicular: relato de caso.
  • Description of a male patient case, 22 years old, presenting visual acuity decrease in the left eye associated with the diagnosis of metastatic testicular tumor to lung and kidney.
  • Evaluation of the evolution of a choroid lesion compatible with ocular metastasis of testis tumor through ophthalmologic and echographic examinations.
  • There was resolution of the intraocular lesion together with lung radiologic improvement after chemotherapy during approximately 4 months of follow-up.
  • In spite of the remission of the ocular lesion, the patient died due to complications of cerebral metastasis.
  • Approached in the literature as rare, no report was found of a case of choroidal metastasis of a testicular site, this being, perhaps, its first description.
  • [MeSH-major] Choroid Neoplasms / secondary. Seminoma / secondary. Testicular Neoplasms
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Fatal Outcome. Humans. Lung Neoplasms / secondary. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273696.001).
  • [ISSN] 0004-2749
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


2. George B, Wirostko WJ, Connor TB, Choong NW: Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy. J Thorac Oncol; 2009 May;4(5):661-2
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy.
  • Ocular metastasis from lung cancer is uncommon.
  • We report a patient with metastatic non-small cell lung cancer who was found to have a metastatic lesion in the choroid at the time of presentation.
  • After three cycles of chemotherapy, radiologic imaging and ophthalmologic examination demonstrated complete resolution of the choroid lesion.
  • This case report demonstrates the durable response of choroidal metastasis from non-small cell lung cancer to systemic bevacizumab and chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Choroid Neoplasms / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19395911.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


3. Hughes B, Yip D, Goldstein D, Waring P, Beshay V, Chong G: Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report. BMC Cancer; 2004 Oct 9;4:74
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report.
  • BACKGROUND: The management of unresectable or metastatic gastrointestinal stromal tumors (GISTs) has previously been difficult as they are resistant to conventional chemotherapy and radiation.
  • We describe the case of a man with metastatic GIST who experienced multiple cerebral relapses of disease while systemic disease progression appeared to be controlled by imatinib.
  • The jejunal primary was resected and after unsuccessful cytoreductive chemotherapy, the liver metastases were also resected in December 1999.
  • The patient subsequently relapsed in August 2001 with symptomatic hepatic, subcutaneous gluteal, left choroidal and right ocular metastases all confirmed on CT and PET scanning.
  • The symptoms improved with objective PET and CT scan response until December 2002 when the patient developed a right-sided foot drop.
  • MRI scan showed a left parasagittal tumor which was resected and confirmed histologically to be metastatic GIST.
  • The left parasagittal metastasis recurred and required subsequent re-excision in September 2003 and January 2004.
  • Control of the systemic GIST was temporarily lost on reduction of the dose of imatinib (due to limited drug supply) but on increasing the dose back to 800 mg per day, systemic disease was stabilized for a period of time before generalised progression occurred.
  • CONCLUSION: This case illustrates that the brain can be a sanctuary site to treatment of GISTs with imatinib.
  • Maintaining dosing of imatinib in the face of isolated sites of disease progression is also important, as other metastatic sites may still be sensitive.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / secondary. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / pathology. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Control. 2001 May-Jun;8(3):252-61 [11378651.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):870-2 [11821475.001]
  • [Cites] Br J Haematol. 2002 Jun;117(3):623-5 [12028032.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Br J Haematol. 2002 Oct;119(1):106-8 [12358909.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] Blood. 2003 Jun 15;101(12):5010-3 [12595307.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4256-8 [14615464.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • (PMID = 15473910.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC524360
  •  go-up   go-down


Advertisement
4. Ino K, Mitsui T, Nomura S, Kikkawa F, Mizutani S: Complete remission of gestational choriocarcinoma with choroidal metastasis treated with systemic chemotherapy alone: case report and review of literature. Gynecol Oncol; 2001 Dec;83(3):601-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of gestational choriocarcinoma with choroidal metastasis treated with systemic chemotherapy alone: case report and review of literature.
  • BACKGROUND: Gestational choriocarcinoma is a malignant tumor that frequently metastasizes to the highly vascularized organs such as the lung, brain, and liver via hematogenous spread.
  • However, this tumor rarely metastasizes to the eye and only a few cases of metastasis to the choroid have been reported.
  • Ophthalmologic evaluation revealed a metastatic choroidal tumor, and a CT scan showed a metastatic tumor in the left lung.
  • A clinical diagnosis of metastatic gestational choriocarcinoma involving the choroid and lung was made.
  • The patient received 13 courses of combination chemotherapy, resulting in complete remission.
  • Radiotherapy and surgical treatment were unnecessary.
  • CONCLUSION: This is a very rare case of the successful treatment of gestational choriocarcinoma metastatic to the choroid using systemic chemotherapy alone.
  • [MeSH-major] Choriocarcinoma / drug therapy. Choriocarcinoma / secondary. Choroid Neoplasms / drug therapy. Choroid Neoplasms / secondary. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2001 Elsevier Science.
  • (PMID = 11733980.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


5. Haritoglou C, Mueller AJ: [Regression of an uveal metastatic tumor from breast cancer during chemotherapy--a case report]. Ophthalmologe; 2003 Apr;100(4):326-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of an uveal metastatic tumor from breast cancer during chemotherapy--a case report].
  • [Transliterated title] Visusanstieg nach Chemotherapie einer Aderhautmetastase eines Mammakarzinoms.
  • BACKGROUND: Choroidal metastases generally respond well to radiation treatment.
  • In these cases, alternatives to radiation, which is a palliative treatment in most cases anyway, should be considered.
  • MATERIAL AND METHODS: We present the clinical and echographic findings of a case of a 39-year-old patient with choroidal metastasis from breast carcinoma.
  • RESULTS: We observed a regression of the metastasis and an improvement of visual acuity from 0.2 to 1.0 under systemic chemotherapy.
  • Echography showed a decrease of tumor height and increasing reflectivity indicating progressive scarring of the lesion.
  • Up to now, the patient has survived 9 years after initial diagnosis.
  • CONCLUSIONS: Especially in cases in which a deterioration of visual acuity after radiation must be expected, the follow-up during systemic chemotherapy alone might be considered an alternative option, as it not only might preserve vision, but also allows an "in vivo" monitoring of the success of the chemotherapy applied.
  • [MeSH-major] Breast Neoplasms. Choroid Neoplasms / secondary. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Combined Modality Therapy. Diphosphonates / administration & dosage. Diphosphonates / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Fluorescein Angiography. Follow-Up Studies. Humans. Tamoxifen / administration & dosage. Tamoxifen / therapeutic use. Time Factors. Visual Acuity

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12682767.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 0 / Diphosphonates; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; OYY3447OMC / pamidronate; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. ElMallah MK, Chernoff AM, Blair NP: Testicular mixed germ-cell tumor metastatic to the choroid. Retin Cases Brief Rep; 2008;2(2):172-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular mixed germ-cell tumor metastatic to the choroid.
  • PURPOSE: To describe the fundus findings, ultrasonography, and fluorescein angiography of a testicular mixed germ-cell tumor metastatic to the choroid and to report prompt resolution of the choroidal lesion with systemic chemotherapy.
  • A 21-year-old man presented with a 10-cm testicular tumor.
  • Ophthalmic examination revealed a large, dome-shaped choroidal lesion in the left eye, filling the entire superotemporal quadrant and extending into the macula.
  • RESULTS: On ophthalmic examination 6 weeks after initiation of chemotherapy, the choroidal lesion had completely resolved, leaving only pigmentary changes.
  • Final ophthalmology follow-up 8 months after presentation demonstrated no recurrence of choroidal metastases.
  • CONCLUSION: Testicular germ-cell tumors have now been well described to metastasize to the choroid.
  • These choroidal metastases can show a prompt, favorable response to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25389834.001).
  • [ISSN] 1935-1089
  • [Journal-full-title] Retinal cases & brief reports
  • [ISO-abbreviation] Retin Cases Brief Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Barbón JJ, González-Tuero J, Gay LL, Pérez-García FJ, Sampedro A: [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy]. Arch Soc Esp Oftalmol; 2007 Nov;82(11):715-7
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
  • [Transliterated title] Regresión de una metástasis coroidea de adenocarcinoma de próstata con tratamiento hormonal.
  • CASE REPORT: We report a case of a patient diagnosed with prostatic adenocarcinoma with multiple bone metastases and a choroidal metastasis in his left eye.
  • Hormonal therapy with an anti-androgen and a LH-RH agonist was followed by regression of the choroidal mass over a period of 2 months.
  • No metastatic recurrence has been demonstrated after a follow-up period of 14 months.
  • DISCUSSION: Complete resolution of choroidal metastases of prostatic adenocarcinoma with hormonal therapy is exceptional, but the effect of this treatment on such metastases should be observed before recommending radiation therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Choroid Neoplasms / secondary. Nitriles / therapeutic use. Prostatic Neoplasms / drug therapy. Tosyl Compounds / therapeutic use
  • [MeSH-minor] Aged. Biopsy. Bone Neoplasms / secondary. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Prostate / pathology. Prostate-Specific Antigen / blood. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979041.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


8. Sari R, Camci C, Kutlu R, Totan Y, Sevinc A, Buyukberber S: The efficacy of acetazolamide on visual functions in a patient with choroid metastasis of breast carcinoma. Int J Clin Pract; 2001 Sep;55(7):488-90
Hazardous Substances Data Bank. ACETAZOLAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of acetazolamide on visual functions in a patient with choroid metastasis of breast carcinoma.
  • Breast carcinoma is the most frequent cancer in women and is the second leading cause of death.
  • Choroid metastasis of breast carcinoma can be found either at presentation or in remission.
  • It is frequently encountered in disseminated breast cancer with multiple organ metastasis.
  • It has been proposed that the oedema-reducing effect of acetazolamide is due to stimulated ion and fluid removal from the retina to the choroid.
  • A 40-year-old female patient on adjuvant chemotherapy for breast cancer was found to have an isolated choroid metastasis.
  • Clinical and radiological remission was achieved after orbital radiotherapy, chemotherapy and acetazolamide treatment.
  • In this case report, we emphasise the possible beneficial effect of acetazolamide in patients with choroid metastasis.
  • [MeSH-major] Acetazolamide / therapeutic use. Breast Neoplasms. Carbonic Anhydrase Inhibitors / therapeutic use. Carcinoma, Ductal, Breast / secondary. Choroid Neoplasms / secondary. Vision Disorders / drug therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11594263.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbonic Anhydrase Inhibitors; O3FX965V0I / Acetazolamide
  •  go-up   go-down


9. Venkatesh P, Garg S: Regression of choroidal metastasis from breast carcinoma following Letrozole therapy. Clin Exp Ophthalmol; 2007 Jul;35(5):492-4
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of choroidal metastasis from breast carcinoma following Letrozole therapy.
  • Metastasis to the choroid from primary tumours elsewhere in the body is not an infrequent occurrence.
  • Management of such metastasis may involve modalities such as radiotherapy, chemotherapy, photocoagulation and surgical resection.
  • The role of hormonal therapy is poorly defined in the management of these tumours.
  • Herein regression of choroidal metastasis from primary breast carcinoma following antihormonal therapy with the antioestrogen drug Letrozole is reported.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Choroid Neoplasms / drug therapy. Estrogen Receptor Modulators / therapeutic use. Nitriles / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Adult. Female. Fluorescein Angiography. Humans. Remission Induction. Tomography, Optical Coherence

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651258.001).
  • [ISSN] 1442-6404
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Estrogen Receptor Modulators; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


10. Tazi N, Le Thi Huong D, Bodaghi B, Rixe O, Lehoang P, Piette JC: [Choroidal metastasis revealing pulmonary adenocarcinoma]. Rev Med Interne; 2006 Sep;27(9):699-701
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroidal metastasis revealing pulmonary adenocarcinoma].
  • Lung cancer is the first cause of choroidal metastasis in man.
  • He presented with visual decrease and metamorphopsia that lead to the diagnosis of a metastatic adenocarcinoma of the lung (bone, liver, choroid, nodles).
  • Chemotherapy permitted to improve visual acuity, in parallel with disappearance of choroidal metatasis.
  • Discovery of choroidal tumor should evoke in first line metastasis.
  • Chemotherapy can improve visual acuity and the quality of life.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872723.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Inoue K, Numaga J, Kaji Y, Toda J, Kato S, Sakurai M, Ikeda M, Motoi N, Murakami T, Fujino Y: Bilateral choroidal metastases secondary to uterocervical carcinoma of the squamous cell type. Am J Ophthalmol; 2000 Nov;130(5):682-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral choroidal metastases secondary to uterocervical carcinoma of the squamous cell type.
  • PURPOSE: To report a patient with bilateral choroidal metastases secondary to uterocervical carcinoma of the squamous cell type.
  • Seven months earlier, uterocervical carcinoma of the squamous cell type was diagnosed and treated with chemotherapy and irradiation.
  • Serous retinal detachment and choroidal masses were present in both eyes.
  • The patient died of respiratory insufficiency 3 months after the appearance of choroidal metastases.
  • At autopsy, there was no second cancer to cause the choroidal metastases.
  • Tumor embolization was present in the choriocapillaries.
  • CONCLUSION: Choroidal metastasis may develop from hematogenous spread of uterocervical squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Choroid Neoplasms / secondary. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11078857.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


12. Akahira J, Konno R, Ito K, Sato S, Yajima A: Choroidal metastasis presented as the initial symptom of the recurrence from ovarian endometrioid adenocarcinoma: A case report. Gynecol Oncol; 2000 Apr;77(1):219-21
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroidal metastasis presented as the initial symptom of the recurrence from ovarian endometrioid adenocarcinoma: A case report.
  • Choroidal metastasis from recurrent ovarian cancer is extremely rare.
  • Ophthalmologic evaluation revealed a metastatic choroidal tumor from ovarian cancer which had been diagnosed 10 years ago.
  • After cesarean section, multiple metastases were found including the choroid, scalp, bone, and lung, and she received four courses of single agent carboplatin chemotherapy.
  • This case highlights the need to investigate the etiology of visual complaints in patients with a history of ovarian cancer even in the early stage.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Choroid Neoplasms / secondary. Ovarian Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis / diagnosis. Neoplasm Recurrence, Local. Pregnancy. Vision Disorders / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10739718.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


13. Fernandes BF, Fernandes LH, Burnier MN Jr: Choroidal mass as the presenting sign of small cell lung carcinoma. Can J Ophthalmol; 2006 Oct;41(5):605-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroidal mass as the presenting sign of small cell lung carcinoma.
  • CASE REPORT: To report the case of a 58-year-old man with blurred vision and metamorphopsia who had an amelanotic choroidal mass in the right eye as the presenting sign of a small cell lung carcinoma.
  • Systemic screening failed to reveal a tumor elsewhere, and the lesion was initially treated as a primary ocular tumor.
  • Discovery of the primary site was made 10 months after the ocular diagnosis, and the patient was then treated with systemic chemotherapy and local radiation therapy.
  • COMMENTS: The ophthalmologist has a crucial role not only in the management of ocular metastases but also in the diagnosis of the primary nonocular malignancies that present as a choroidal mass.
  • The possibility of ocular metastases in patients with choroidal masses should always be considered whether or not there is a diagnosis of cancer elsewhere.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17016534.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Barbazetto I, Schmidt-Erfurth U: Photodynamic therapy of choroidal hemangioma: two case reports. Graefes Arch Clin Exp Ophthalmol; 2000 Mar;238(3):214-21
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of choroidal hemangioma: two case reports.
  • Depending on the location of the angioma, these treatments can cause additional, significant functional damage.
  • Photodynamic therapy (PDT) however, allows a selective occlusion of vascular lesions without damaging adjacent retinal structures.
  • METHODS: Two patients with isolated choroidal hemangiomas involving the posterior pole were treated with PDT.
  • Treatments were performed using a diode laser at 692 nm, a light dose of 100 J/cm2 and 6 mg/m2 body surface area verteporfin (BPD-MA).
  • RESULTS: Tumor heights were 3.3 and 4.6 mm on pretreatment ultrasound.
  • After therapy, patients with isolated choroidal hemangioma showed total regression of the lesion and improved visual acuity due to resorption of retinal edema.
  • Ultrasound demonstrated a progressive decrease in tumor height after each PDT application, with complete disappearance of the lesion.
  • Retinal vessels were not affected by the treatment, and retinal function recovered in areas with previous tumor involvement.
  • CONCLUSION: PDT allows selective treatment of large intraocular angiomatous lesions.
  • Without optimized parameters, complete regression of choroidal hemangiomas, resolution of secondary complications and improvement of visual acuity were documented.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Adult. Female. Fluorescein Angiography. Humans. Indocyanine Green. Lasers. Male. Middle Aged. Treatment Outcome. Visual Acuity

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10796035.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 113719-89-4 / benzoporphyrin D; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


15. Kodama M, Kawaguchi H, Komoto Y, Takemura M: Coexistent intramedullary spinal cord and choroidal metastases in ovarian cancer. J Obstet Gynaecol Res; 2010 Feb;36(1):199-203
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistent intramedullary spinal cord and choroidal metastases in ovarian cancer.
  • Involvement of intramedullary spinal cord and the choroid by ovarian cancer is rare, and coexistence of metastases at these sites is extremely rare and has never been reported.
  • This condition rapidly progresses to a neurological emergency; however, an efficient standard treatment method is not available for this rare condition.
  • She presented with blindness and other neurologic complaints during the course of treatment for a recurrence at 50 months after the primary surgical treatment for the tumor.
  • Magnetic resonance imaging (MRI) revealed intramedullary spinal cord metastasis and choroidal metastasis, coexisting with multiple brain metastases and intra-abdominal lesions.
  • Neurological emergency was prevented by administering whole-brain irradiation therapy followed by systemic chemotherapy.
  • Early diagnosis and multidisciplinary treatment, including radiotherapy and chemotherapy, may offer good palliation for such unusual metastases of ovarian cancer.
  • [MeSH-major] Brain Neoplasms / secondary. Choroid Neoplasms / secondary. Cystadenocarcinoma, Serous / secondary. Neoplasm Recurrence, Local. Ovarian Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Abdominal Neoplasms / secondary. Abdominal Neoplasms / therapy. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Hysterectomy. Ovariectomy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20178552.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


16. Porrini G, Giovannini A, Amato G, Ioni A, Pantanetti M: Photodynamic therapy of circumscribed choroidal hemangioma. Ophthalmology; 2003 Apr;110(4):674-80
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of circumscribed choroidal hemangioma.
  • PURPOSE: To evaluate the safety and effectiveness of photodynamic therapy (PDT) in the treatment of symptomatic circumscribed choroidal hemangiomas (CCH) of the posterior pole.
  • METHODS: Photodynamic therapy was applied by Zeiss laser (Visulas 6905, Carl Zeiss-Meditech AG, Jeud Germany) emitting a light at 689 nm for photosensitization and by using verteporfin (Visudyne; Novartis Ophthalmics AG, Basel, Switzerland) at a dose of 6 mg/m(2) body surface administered intravenously before treatment.
  • The diameter of the treatment spot was calculated on early frames of pretreatment indocyanine green angiography; the maximum treatment spot diameter was 6000 micro m using a Mainster wide-field lens (Ocular Instruments Inc., Bellevue, WA USA).
  • Two different treatment procedures were used according to the height of the lesion.
  • A radiant exposure of 100 J/cm(2) with an exposure time of 186 seconds was applied to lesions larger than 2 mm.
  • For lesions smaller than 2 mm, a radiant exposure of 75 J/cm(2) with an exposure time of 125 seconds was used.
  • RESULTS: After a follow-up of 7 to 16 months, FA and ICGA verified the nonperfusion of the vascular channels of the tumor in the treated areas.
  • No retinal pigment epithelium (RPE) changes were observed in the patients who had undergone two PDT treatments, whereas minimal alterations were detected in two of the four patients who had undergone three treatment sessions.
  • Ultrasound examination found no measurable tumor height in six (60%) cases and a marked reduction in the remaining four cases, even after one treatment (post treatment tumor height range, 0.86-1.82 mm).
  • An improvement in visual acuity (one to six lines on the Early Treatment for Diabetic Retinopathy Study chart) was observed in all the cases.
  • In four cases, the visual acuity returned to 20/20, of which three were extrafoveal and one was subfoveal with visual impairment caused by secondary exudative macular detachment without significant RPE alterations.
  • CONCLUSIONS: Photodynamic therapy is a minimally invasive but effective method of treatment for CCH and may be considered as a treatment of choice, especially in patients with foveal location of the tumor.
  • Because of its safety and repeatability, this technique can be used to treat frequent recurrences of the tumor.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma, Capillary / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Adult. Aged. Coloring Agents. Female. Fluorescein Angiography. Humans. Indocyanine Green. Male. Middle Aged. Prospective Studies. Safety. Treatment Outcome. Visual Acuity

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12689885.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


17. Schmidt D, Ness T, Geissler M: Cotton-wool spots associated with pancreatic carcinoma. Eur J Med Res; 2001 Mar 26;6(3):101-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant tumors of different organs may cause changes in the eye.
  • In addition, the man revealed a metastasis of the choroid in the right eye.
  • The cotton-wool spots were reduced in size in the woman after treatment with Gemcitabine.
  • After termination of treatment, their general condition deteriorated and they died within a few weeks.
  • [MeSH-minor] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / secondary. Biomarkers, Tumor / metabolism. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Eye Neoplasms / diagnosis. Eye Neoplasms / drug therapy. Eye Neoplasms / secondary. Fatal Outcome. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11309222.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


18. Amer R, Pe'er J, Chowers I, Anteby I: Treatment options in the management of choroidal metastases. Ophthalmologica; 2004 Nov-Dec;218(6):372-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options in the management of choroidal metastases.
  • We performed a retrospective study of 40 consecutive patients (50 eyes) treated for choroidal metastases of solid systemic malignancies in order to evaluate treatment results.
  • Patients received either systemic or local therapy or a combination of both.
  • The most common primary tumor was breast carcinoma (62.5%).
  • Systemic chemotherapy alone was used in 13.3% of eyes, local therapy alone in 44.4%, and a combination of both in 42.2% of eyes.
  • Local treatment modalities included brachytherapy, external beam irradiation, and laser photocoagulation.
  • Complete regression of the choroidal metastases was seen in 57.8% of eyes, partial regression in 15.6 and no response in 4.4%; 22.2% were not available for re-evaluation.
  • We have concluded that the treatment modality in patients with metastatic ocular disease should be individually tailored.
  • When ocular metastases are concurrent with widespread metastatic disease, systemic chemotherapy alone or in combination with local therapy is reasonable.
  • In patients manifesting metastases in the eyes alone, local therapy modalities may be safe, allowing conservation of visual functions with minimal systemic morbidity.
  • [MeSH-major] Choroid Neoplasms / secondary. Choroid Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Brachytherapy. Combined Modality Therapy. Female. Humans. Laser Coagulation. Male. Middle Aged. Neoplasms / pathology. Neoplasms / therapy. Retrospective Studies. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel.
  • (PMID = 15564754.001).
  • [ISSN] 0030-3755
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Boixadera A, García-Arumí J, Martínez-Castillo V, Encinas JL, Elizalde J, Blanco-Mateos G, Caminal J, Capeans C, Armada F, Navea A, Olea JL: Prospective clinical trial evaluating the efficacy of photodynamic therapy for symptomatic circumscribed choroidal hemangioma. Ophthalmology; 2009 Jan;116(1):100-105.e1
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective clinical trial evaluating the efficacy of photodynamic therapy for symptomatic circumscribed choroidal hemangioma.
  • PURPOSE: To evaluate photodynamic therapy (PDT) for symptomatic circumscribed choroidal hemangioma (CCH).
  • INTERVENTION: Photodynamic therapy was applied by Zeiss laser.
  • Intravenous verteporfin at 6 mg/m(2) body surface was administered before treatment, and light emitted at 689 nm for photosensitization.
  • The treatment spot diameter was calculated on early-phase frames of pretreatment indocyanine green angiography.
  • Fifteen minutes after starting the verteporfin infusion, the laser beam was applied to the retina at radiant exposure 50 J/cm(2) and exposure time 83 seconds.
  • One to 4 treatments were applied at 12-week intervals over 1 year.
  • Standardized evaluation was performed before and at 4-week intervals after each treatment, and at 3, 6, 9, and 12 months.
  • MAIN OUTCOME MEASURES: The primary outcome measure was the absence of exudative retinal detachment at the 12-month follow-up visit on ophthalmoscopy, fluorescein angiography, and optical coherence tomography.
  • Secondary measures were the visual acuity outcome, with best-corrected visual acuity determined by the Early Treatment for Diabetic Retinopathy Study chart, tumor thickness decrease on B-scan ultrasonography, and adverse events.
  • The CCH thickness decreased in all cases from a mean of 3.0 to 1.7 mm, with the most intense effect seen after 4 weeks of treatment (P<0.001).
  • CONCLUSIONS: Combining PDT with the standard age-related macular degeneration protocol is an effective treatment for CCH in terms of resolution of exudative subretinal fluid and recovery of VA.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Adult. Aged. Coloring Agents. Female. Fluorescein Angiography. Humans. Indocyanine Green. Male. Middle Aged. Prospective Studies. Tomography, Optical Coherence. Treatment Outcome. Visual Acuity

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ophthalmology. 2009 May;116(5):822. Arumí, José García [corrected to García-Arumí, José]
  • (PMID = 18973950.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


20. Cormio G, Martino R, Loizzi V, Resta L, Selvaggi L: A rare case of choroidal metastasis presented after conservative management of endometrial cancer. Int J Gynecol Cancer; 2006 Nov-Dec;16(6):2044-8
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of choroidal metastasis presented after conservative management of endometrial cancer.
  • Hematogenous dissemination from endometrial cancer is quite rare.
  • We report a 31-year-old woman who developed choroidal metastasis following conservative management of early-stage endometrial carcinoma.
  • Three years after hysterectomy for persistent endometrial carcinoma, she developed multiple metastatic disease (to both lungs and right pelvis), and while on treatment with paclitaxel and carboplatin, she complained of a rapid visual deterioration.
  • Ophthalmologic evaluation revealed a metastatic choroidal tumor associated with multiple central nervous system metastases.
  • The patient refused further treatment and died 1 month after diagnosis of choroidal involvement.
  • In conclusion, this is the first reported case of choroidal metastasis from endometrial cancer and highlights the need to consider immunosuppressive treatment as an absolute contraindication to conservative fertility-sparing treatment in gynecological malignancies.
  • [MeSH-major] Choroid Neoplasms / pathology. Choroid Neoplasms / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Prednisone / therapeutic use

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177844.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] VB0R961HZT / Prednisone
  •  go-up   go-down


21. Kociecki J, Biczysko W, Alugail AW: [Secondary retinal detachment accompanying intraocular tumors]. Klin Oczna; 2004;106(1-2):39-44
MedlinePlus Health Information. consumer health - Retinal Detachment.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Secondary retinal detachment accompanying intraocular tumors].
  • PURPOSE: Aim of the study--the attempt to answer, what is the present incidence mechanism of arising, and what parameters can influence the development of secondary retinal detachment (s. r. d.) caused by intraocular choroidal tumor.
  • MATERIAL AND METHOD: 107 eyes of 105 consecutive patients aged 21 to 82 years (mean 62 years), diagnosed clinically as having choroidal malignant tumor, were evaluated.
  • The cause of s. r. d. was primary malignant choroidal tumor and in 3 cases--metastatic tumor.
  • The therapy included brachytherapy, diode laser transpupillary thermotherapy (TTT), chemotherapy, local tumor excision and combined treatment.
  • The s. r. d. was observed in cases of small tumors (2.77 mm) as well as very large ones (up to 11.56 mm).
  • After therapy the detachment conceded in 10 eyes (37%).
  • Analysis of clinical images, fluorescein angiograms and histopathological evaluation enabled better understanding of mechanisms leading to s. r. d.
  • In evaluated group the s. r. d. occurred more often in women (62%) than in men (38%).
  • 3. The s. r. d. may occur in large tumors (over 6 mm) as well as in small ones (3 mm).
  • 4. In case of large tumors the detachment has mainly "mechanical" character, however it may be also influenced by increased permeability of tumor vessels and impaired function of retinal pigment epithelium; the latter mechanism seems to play the main role in case of small tumors; in both cases the external retinal layer is damaged.
  • 5. The most common cause of s. r. d. are tumors located in posterior pole (45%) and least frequently in upper-temporal quadrant (7%).
  • 6. After brachytherapy, TTT or local tumor excision in selected cases s. r. d. may totally regress.
  • [MeSH-major] Choroid Neoplasms / complications. Retina / pathology. Retinal Detachment / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Incidence. Male. Middle Aged. Poland / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15218763.001).
  • [ISSN] 0023-2157
  • [Journal-full-title] Klinika oczna
  • [ISO-abbreviation] Klin Oczna
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


22. Shields CL, Materin MA, Marr BP, Mashayekhi A, Shields JA: Resolution of advanced cystoid macular edema following photodynamic therapy for choroidal hemangioma. Ophthalmic Surg Lasers Imaging; 2005 May-Jun;36(3):237-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resolution of advanced cystoid macular edema following photodynamic therapy for choroidal hemangioma.
  • His visual acuity was 20/200 secondary to a subtle juxtapapillary choroidal hemangioma producing profound cystoid macular edema, with the affected retina measuring 330 microns thick by optical coherence tomography.
  • One month following photodynamic therapy to the tumor using verteporfin, the cystoid macular edema completely resolved, foveal anatomy returned to normal, optical coherence tomography thickness was 179 microns, and visual acuity recovered to 20/25.
  • Photodynamic therapy of choroidal hemangioma may be effective in resolving associated cystoid macular edema and improving visual acuity.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Macular Edema / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Fluorescein Angiography. Humans. Male. Middle Aged. Tomography, Optical Coherence. Visual Acuity

  • Genetic Alliance. consumer health - Edema.
  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15957481.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


23. Wiegel T, Bottke D, Kreusel KM, Schmidt S, Bornfeld N, Foerster MH, Hinkelbein W, German Cancer Society: External beam radiotherapy of choroidal metastases--final results of a prospective study of the German Cancer Society (ARO 95-08). Radiother Oncol; 2002 Jul;64(1):13-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External beam radiotherapy of choroidal metastases--final results of a prospective study of the German Cancer Society (ARO 95-08).
  • PURPOSE: In 1994 a prospective study of the 'Arbeitsgemeinschaft Radiologische Onkologie' of the German Cancer Society was initiated to examine the results of a standardized radiation therapy for choroidal metastases with 40 Gy.
  • Recommendations in the literature vary from 21 to 50 Gy of total dose and from 2 to 5 Gy per single fraction.
  • Thirty-five patients (70%) had unilateral and 15 patients (30%) had bilateral choroidal metastases.
  • Thirty-one patients (62%) had breast cancer and 13 patients (26%) lung cancer as the primary tumor.
  • Patients were treated with 40 Gy in 20 fractions with bilateral asymmetric fields for bilateral or a unilateral field for unilateral choroidal metastasis.
  • Seventeen patients had additional chemotherapy after radiotherapy for general tumor progression.
  • The median survival of all patients was 7 months and for patients with breast cancer 10 months.
  • No patient with asymptomatic metastasis (n = 15 eyes) developed ocular symptoms during follow-up.
  • No patient with unilateral tumor and unilateral irradiation developed contralateral metastasis.
  • Severe side effects, possibly related to tumor progression, occurred in three eyes (5%).
  • CONCLUSION: Radiation therapy with 40 Gy is an effective and safe palliative treatment for symptomatic and asymptomatic choroidal metastases to preserve vision in the majority of the patients.
  • A unilateral field for unilateral metastasis seems to be sufficient to prevent contralateral disease.
  • Side effects of radiotherapy are acceptable: 50% of patients developed a mild skin erythema and conjunctivitis (RTOG I).
  • [MeSH-major] Choroid Neoplasms / radiotherapy. Choroid Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Elsevier Science Ireland Ltd.
  • (PMID = 12208569.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


24. Read RW, Green RL, Rao NA: Metastatic adenocarcinoma with rupture through the Bruch membrane simulating a choroidal melanoma. Am J Ophthalmol; 2001 Dec;132(6):943-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma with rupture through the Bruch membrane simulating a choroidal melanoma.
  • PURPOSE: To report a case of adenocarcinoma metastatic to the choroid with rupture through the Bruch membrane, thus, simulating a choroidal melanoma.
  • RESULTS: A 62-year-old Hispanic female presented with visual loss, right eye, of short duration because of a choroidal mass with retinal detachment.
  • Ultrasonography showed a dome-shaped lesion with an eccentric collar-button projection and medium internal reflectivity, which suggested a choroidal melanoma.
  • Severe pain necessitated enucleation, RE, and histopathology of the choroidal mass demonstrated an adenocarcinoma.
  • CONCLUSION: Metastatic choroidal tumors may present, although rarely, with collar-button configurations.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / pathology. Bruch Membrane / pathology. Choroid Neoplasms / secondary. Melanoma / diagnosis. Retinal Detachment / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / drug therapy. Diagnosis, Differential. Eye Enucleation. Female. Fluorescein Angiography. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Middle Aged. Pain / diagnosis. Rupture, Spontaneous

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11730672.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Blasi MA, Tiberti AC, Scupola A, Balestrazzi A, Colangelo E, Valente P, Balestrazzi E: Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: five-year outcomes. Ophthalmology; 2010 Aug;117(8):1630-7
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: five-year outcomes.
  • OBJECTIVE: To evaluate the long-term efficacy of verteporfin photodynamic therapy (PDT) as the primary treatment for symptomatic circumscribed choroidal hemangioma (CCH).
  • All patients had recent onset of visual symptoms and evidence of exudative macular changes on fluorescein angiography (FA) and optical coherence tomography (OCT).
  • Evaluation of best-corrected visual acuity (BCVA) using Early Treatment of Diabetic Retinopathy Study (ETDRS) criteria, FA, indocyanine green angiography (ICGA), OCT, and ultrasound were performed before PDT and on follow-up examinations.
  • Secondary measures were tumor thickness decrease, absence of leakage on FA, and adverse events.
  • No treatment-related adverse events or complications were identified.
  • CONCLUSIONS: The 5-year results of PDT in treating symptomatic CCH support treatment with a light dose of 100 J/cm(2) after slow intravenous infusion of verteporfin to stabilize or improve visual acuity and resolution of macular exudation.
  • [MeSH-major] Choroid Neoplasms / drug therapy. Hemangioma / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Fluorescein Angiography. Follow-Up Studies. Humans. Indocyanine Green. Male. Middle Aged. Prospective Studies. Tomography, Optical Coherence. Treatment Outcome. Visual Acuity / physiology

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20417564.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


26. Hasturk S, Soylu M, Zeren EH, Hanta I: Basaloid large cell lung carcinoma presenting concurrently with metastatic uveal tumor. Lung Cancer; 2001 Apr;32(1):95-101
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid large cell lung carcinoma presenting concurrently with metastatic uveal tumor.
  • Ultrasonographic examination and orbital magnetic resonance imaging (MRI) were reported as choroidal metastasis.
  • A computed tomography (CT) confirmed the mass in the left hilum and multiple mass lesions consistent with metastasis in the liver and in the body of 12th thoracic vertebra.
  • He died after 4 months with rapid progression of the disease in spite of combined chemotherapy.
  • Although primary lung cancer with concurrent eye metastasis is an uncommon entity, it should always be kept in mind for patients with ocular symptoms.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / secondary. Lung Neoplasms / pathology. Uveal Neoplasms / pathology. Uveal Neoplasms / secondary
  • [MeSH-minor] Carboplatin / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Paclitaxel / therapeutic use. Pleural Effusion, Malignant / pathology. Smoking / adverse effects. Tomography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11282434.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


27. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N: Adverse events after intravitreal infliximab (Remicade). Retina; 2010 Jan;30(1):71-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To determine the tolerability of intravitreal infliximab (Remicade) in patients with refractory diabetic macular edema or choroidal neovascularization secondary to age-related macular degeneration.
  • METHODS: This is a prospective, interventional, noncomparative, open-label, 12-week pilot study of intravitreal infliximab in four patients who failed conventional therapies.
  • Two had diabetic macular edema and two had choroidal neovascularization secondary to age-related macular degeneration.
  • All patients received 0.5 mg/0.05 mL intravitreal infliximab and were eligible for a second injection at 6 weeks if reinjection criteria were met.
  • Outcome measures were best-corrected visual acuity using standard Early Treatment Diabetic Retinopathy Study refraction, central retinal thickness on optical coherence tomography, fluorescein angiography, standard electroretinography, and microperimetry.
  • All patients had persistence of cystoid macular edema on optical coherence tomography, although two had a decrease in central retinal thickness.
  • The first patient entered in the study met the criteria for a second injection because of improved standard electroretinography and microperimetry at Week 6.
  • However, 2 weeks after the second injection, he developed panuveitis.
  • Three patients developed systemic antibodies against infliximab (human antichimeric antibodies).
  • [MeSH-major] Anti-Inflammatory Agents / adverse effects. Antibodies, Anti-Idiotypic / blood. Antibodies, Monoclonal / adverse effects. Panuveitis / chemically induced. Retina / drug effects
  • [MeSH-minor] Aged. Chimera / immunology. Choroidal Neovascularization / drug therapy. Choroidal Neovascularization / etiology. Diabetic Retinopathy / complications. Diabetic Retinopathy / drug therapy. Electroretinography. Female. Fluorescein Angiography. Follow-Up Studies. Humans. Infliximab. Injections. Macular Degeneration / complications. Macular Degeneration / drug therapy. Macular Edema / drug therapy. Macular Edema / etiology. Male. Middle Aged. Pilot Projects. Prospective Studies. Tomography, Optical Coherence. Tumor Necrosis Factor-alpha / antagonists & inhibitors. Tumor Necrosis Factor-alpha / immunology. Visual Acuity / physiology. Visual Field Tests. Vitreous Body

  • Hazardous Substances Data Bank. Infliximab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19996827.001).
  • [ISSN] 1539-2864
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


28. Soysal HG: Metastatic tumors of the uvea in 38 eyes. Can J Ophthalmol; 2007 Dec;42(6):832-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic tumors of the uvea in 38 eyes.
  • BACKGROUND: The reported incidence of metastatic uveal tumors has been increasing.
  • The aim of this study is to report the clinical features, management, and prognosis of uveal metastatic tumors seen in a general oncology hospital.
  • METHODS: The records of 28 patients with uveal metastasis diagnosed between 1999 and 2006 were reviewed retrospectively.
  • RESULTS: Uveal metastatic tumours were detected in a total of 38 eyes, uveal involvement included the iris in 4 eyes and the choroid in 37 eyes.
  • The primary cancer site was the breast in 24 patients, the lung in 2 patients, the ovary in 1 patient, and the gastrointestinal tract in 1 patient.
  • Choroidal metastases typically were creamy yellow in color, plateau or dome-shaped, and associated with secondary retinal detachment in 56.8% of eyes.
  • The mean time interval between ocular and systemic diagnosis was 41.07 months.
  • At the time of ocular diagnosis, 75% of patients had systemic metastasis.
  • Eight eyes were treated with chemotherapy and hormone therapy, and external beam radiotherapy was applied to 30 eyes.
  • Lesions commonly responded well to therapy, but 22 patients died as a result of disseminated systemic disease.
  • INTERPRETATION: Patients with uveal metastasis generally present to ophthalmologists with visual symptoms but may be asymptomatic in some cases.
  • Local tumor control can be managed with current therapy, but systemic prognosis is generally poor because of the disseminated stage of the malignant disease.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17985001.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


29. Markomichelakis NN, Theodossiadis PG, Sfikakis PP: Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol; 2005 Mar;139(3):537-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of neovascular age-related macular degeneration following infliximab therapy.
  • PURPOSE: To describe the effects of the antitumor necrosis factor (TNF) monoclonal antibody Infliximab systemic therapy on choroidal neovacularisation (CNV) secondary to age-related macular degeneration (AMD).
  • METHODS: A subretinal membrane secondary to AMD was documented by fluoroangiography at baseline in three elderly patients scheduled to receive Infliximab therapy for inflammatory arthritis (infusions of 5 mg/kg at weeks 0, 2, 6, and every 8 weeks thereafter).
  • Follow-up was performed at three months post-baseline, as well as during 18 months of continuing treatment in the first patient.
  • CONCLUSIONS: These findings suggest a plausible pathogenetic role of TNF in CNV secondary to AMD.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Choroidal Neovascularization / drug therapy. Macular Degeneration / drug therapy. Tumor Necrosis Factor-alpha / immunology

  • Genetic Alliance. consumer health - Macular Degeneration.
  • MedlinePlus Health Information. consumer health - Macular Degeneration.
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767068.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


30. Neitzke R, Spraul CW, Lang GE, Lang GK: [Iris metastases in breast carcinoma]. Ophthalmologe; 2001 Nov;98(11):1097-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Metastatic cancer of the iris is rare.
  • METHOD: A 60-year-old woman with a history of breast carcinoma presented with lesions of the iris 5 years after diagnosis and tumor excision.
  • In addition to slit-lamp examination including gonioscopy, ultrasound biomicroscopy, positron-emission tomography and fluorescein angiography of the iris were used for diagnosis.
  • RESULTS: The iris metastasis exhibited multiple whitish to pink nodules on the inferior half of the iris and infiltration of the chamber angle.
  • The main tumor mass was prominent and highly vascularized.
  • Ultrasound biomicroscopy showed lobular masses characterized by mid to low reflectivity and there was no distinct border to the surrounding tissue.
  • Fluorescein angiography of the iris showed tumor vessels with dye leakage.
  • The positron-emission tomography displayed metastatic lesions to the liver, lung, bones and lymph nodules in addition to the lesion of the iris.
  • The review of the literature revealed that breast carcinoma leads to choroidal metastases in 5% of cases and iris metastases are even rarer.
  • The preferred treatment is chemotherapy and/or radiation therapy.
  • CONCLUSIONS: Breast carcinoma is rarely associated with iris metastasis.
  • Positron-emission tomography is a sensitive diagnostic tool to identify metastatic lesions and is a useful method for planning therapeutic approaches.
  • Radiation therapy, argon laser treatment and block excision are therapeutic options with an isolated metastasis of the iris.
  • [MeSH-major] Breast Neoplasms. Iris Neoplasms / secondary
  • [MeSH-minor] Female. Fluorescein Angiography. Gonioscopy. Humans. Microscopy. Middle Aged. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11729744.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Shields JA, Perez N, Shields CL, Singh AD, Eagle RC Jr: Orbital melanoma metastatic from contralateral choroid: management by complete surgical resection. Ophthalmic Surg Lasers; 2002 Sep-Oct;33(5):416-20
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for orbital melanoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital melanoma metastatic from contralateral choroid: management by complete surgical resection.
  • We discuss a clinicopathologic correlation of orbital metastasis from a contralateral choroidal melanoma wherein the orbital tumor was removed completely by surgical resection.
  • In October 1982, a 29-year-old woman was treated with cobalt-60 plaque radiotherapy for a choroidal melanoma in her right eye.
  • The tumor responded well but recurred after 9 years, necessitating enucleation.
  • In August 1999, 17 years after initial presentation, metastatic melanoma to liver, lung, and brain were found and the patient had a favorable response to chemotherapy and brain irradiation.
  • Complete surgical removal of the tumor was achieved by a superotemporal orbitotomy.
  • Histopathologically, the tumor was a malignant melanoma with features similar to the choroidal tumor.
  • The contralateral orbit can be the site of late metastasis from choroidal melanoma.
  • In rare instances, an orbital metastasis can be completely removed surgically without subjecting the patient to orbital irradiation.
  • [MeSH-major] Choroid Neoplasms / pathology. Melanoma / secondary. Orbital Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12358296.001).
  • [ISSN] 1082-3069
  • [Journal-full-title] Ophthalmic surgery and lasers
  • [ISO-abbreviation] Ophthalmic Surg Lasers
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


32. Gupta A, Muecke JS: Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). Retina; 2008 Jul-Aug;28(7):964-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin).
  • PURPOSE: To evaluate the safety and efficacy of intravitreal injection of bevacizumab as a treatment option for radiation maculopathy secondary to plaque radiotherapy.
  • METHODS: Interventional case series of five patients who developed radiation maculopathy complicating plaque radiotherapy with ruthenium 106 for choroidal melanoma.
  • The main outcome measures were visual acuity and results of clinical ophthalmic examination and optical coherence tomography.
  • The average preinjection central macular thickness measured by optical coherence tomography was 351 microm.
  • Three of five patients had no improvement in macular edema after treatment with a single injection of bevacizumab at the 2-week follow-up (average postinjection central macular thickness, 287 microm).
  • Maculopathy in these two patients was diagnosed 1 week before treatment was offered.
  • All but one patient (Patient 5; dose, 8,000 cGy) received a radiation dose of 10,000 cGy to the tumor apex.
  • CONCLUSIONS: In this series, treatment of radiation maculopathy with intravitreal injection of bevacizumab was useful in two patients as measured by improvement in visual acuity due to resolution of macular edema.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Macula Lutea / radiation effects. Radiation Injuries / drug therapy. Retinal Diseases / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Brachytherapy / adverse effects. Choroid Neoplasms / radiotherapy. Female. Follow-Up Studies. Humans. Injections. Male. Melanoma / radiotherapy. Middle Aged. Retreatment. Retrospective Studies. Ruthenium Radioisotopes / adverse effects. Tomography, Optical Coherence. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Visual Acuity. Vitreous Body

  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698298.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Ruthenium Radioisotopes; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down






Advertisement